Literature DB >> 18651887

Interleukin-4 -590 (C>T), toll-like receptor-2 +2258 (G>A) and matrix metalloproteinase-9 -1562 (C>T) polymorphisms in pre-eclampsia.

R Fraser1, J J Walker, U V Ekbote, K L Martin, P McShane, N M Orsi.   

Abstract

Functional single nucleotide polymorphisms (SNPs) of interleukin (IL)-4 -590 (C>T), toll-like receptor (TLR)-2 +2258 (G>A) and matrix metalloproteinase (MMP)-9 -1562 (C>T) were examined by polymerase chain reaction-restriction fragment length polymorphism to identify their merit as genetic markers for pre-eclampsia. One hundred and seventeen pre-eclamptic women and 146 control subjects with uncomplicated singleton pregnancies participated in this study, conducted at Leeds General Infirmary and St James's University Hospital. While the TLR-2 +2258 (G>A) and MMP-9 -1562 (C>T) SNPs failed to present any significant association with pre-eclampsia, there was a marked trend for an association between the IL-4 -590 (C>T) SNP and pre-eclampsia (chi(2)= 5.87, P = 0.055), with a prevalence of TT homozygous women in this group (OR 4.455, 95% CI 1.286-15.350).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18651887     DOI: 10.1111/j.1471-0528.2008.01771.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  9 in total

Review 1.  Candidate Gene, Genome-Wide Association and Bioinformatic Studies in Pre-eclampsia: a Review.

Authors:  Semone Thakoordeen; Jagidesa Moodley; Thajasvarie Naicker
Journal:  Curr Hypertens Rep       Date:  2018-08-29       Impact factor: 5.369

Review 2.  Matrix metalloproteinases as drug targets in preeclampsia.

Authors:  Ana C T Palei; Joey P Granger; Jose E Tanus-Santos
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

Review 3.  Pregnancy, preeclampsia and maternal aging: From epidemiology to functional genomics.

Authors:  Eliza C Miller; Ashley Wilczek; Natalie A Bello; Sarah Tom; Ronald Wapner; Yousin Suh
Journal:  Ageing Res Rev       Date:  2021-12-03       Impact factor: 10.895

4.  Association of Nitric Oxide Synthase and Matrix Metalloprotease Single Nucleotide Polymorphisms with Preeclampsia and Its Complications.

Authors:  Daniela P Leonardo; Dulcinéia M Albuquerque; Carolina Lanaro; Letícia C Baptista; José G Cecatti; Fernanda G Surita; Mary A Parpinelli; Fernando F Costa; Carla F Franco-Penteado; Kleber Y Fertrin; Maria Laura Costa
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

Review 5.  Inflammatory pattern recognition receptors and their ligands: factors contributing to the pathogenesis of preeclampsia.

Authors:  Toshiyuki Sado; Katsuhiko Naruse; Taketoshi Noguchi; Shoji Haruta; Shozo Yoshida; Yasuhito Tanase; Takashi Kitanaka; Hidekazu Oi; Hiroshi Kobayashi
Journal:  Inflamm Res       Date:  2011-03-06       Impact factor: 4.575

6.  Effects of TIMP1 rs4898 Gene Polymorphism on Early-Onset Preeclampsia Development and Placenta Weight.

Authors:  Aleksandra E Mrozikiewicz; Grażyna Kurzawińska; Agata Goździewicz-Szpera; Michał Potograbski; Marcin Ożarowski; Tomasz M Karpiński; Magdalena Barlik; Piotr Jędrzejczak; Krzysztof Drews
Journal:  Diagnostics (Basel)       Date:  2022-07-05

Review 7.  Cytokine-polymorphisms associated with Preeclampsia: A review.

Authors:  Carlos Mora-Palazuelos; Mercedes Bermúdez; Maribel Aguilar-Medina; Rosalío Ramos-Payan; Alfredo Ayala-Ham; Jose Geovanni Romero-Quintana
Journal:  Medicine (Baltimore)       Date:  2022-09-30       Impact factor: 1.817

8.  Possible association of IL-4 VNTR polymorphism with susceptibility to preeclampsia.

Authors:  Saeedeh Salimi; Milad Mohammadoo-Khorasani; Minoo Yaghmaei; Mojgan Mokhtari; Maryam Moossavi
Journal:  Biomed Res Int       Date:  2014-04-28       Impact factor: 3.411

Review 9.  New Insights into the Role of Matrix Metalloproteinases in Preeclampsia.

Authors:  Salvador Espino Y Sosa; Arturo Flores-Pliego; Aurora Espejel-Nuñez; Diana Medina-Bastidas; Felipe Vadillo-Ortega; Veronica Zaga-Clavellina; Guadalupe Estrada-Gutierrez
Journal:  Int J Mol Sci       Date:  2017-07-20       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.